A Phase 3 interventional study of Secukinumab and Secukinumab and Placebo in Axial Psoratic Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 94 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-01.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 6th largest by enrollment, is one of 5 that started in 2016, is one of 16 in phase 3, and was the 13th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 503 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 231 across the 26 interventional studies. Of the 22 that completed or were terminated, 17 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 26 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
31 studies in Arthritis, Psoriatic by Novartis: 3 open now, 3 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 31 studies in Arthritis, Psoriatic by Novartis, this one is the 5th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2016, is one of 14 in phase 3, and was the 12th registered.
Novartis’s Arthritis, Psoriatic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 31 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 150 mg or 300 mg in the management of axial manifestations in PsA patients who have failed to respond to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) over a 4-week period, according to assessment of spondyloarthritis international society (ASAS) recommendations for the treatment of axial spondyloarthritis (AxSpA).
In the anlalysis (CSR), there are 498 patients, as 5 patients were mis-randomized, i.e. had randomization number but did never take study medication. So there were 498 participants, and not 503
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria may have applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Secukinumab dose amount 1 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 1 sc injection every 4 weeks for remaining 44 weeks
Biological: Secukinumab
Secukinumab dose amount 2 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 2 sc injection every 4 weeks for remaining 44 weeks
Biological: Secukinumab
Placebo sc injection weekly for 4 weeks and at week 8, followed by Secukinumab 150 mg or 300 mg sc injection every 4 week for remaining 40 weeks.
Biological: Secukinumab · Drug: Secukinumab and Placebo
Anti IL-17a monoclonal antibody
Also known as: AIN457
Placebo matching AIN457
Percentage of Participants With Response to Treatment (300 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12
Purpose of this measure: was to demonstrate that secukinumab 150 mg s.c. is superior to placebo in the achievement of ASAS 20 response at Week 12 after superiority of 300 mg was established ASAS20 was defined as an improvement of ≥20% and absolute improvement of ≥10 unit (0-100 mm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (total pain score), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)
Time frame: at week 12
Percentage of Participants With Response to Treatment (150 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12
Purpose of this key secondary measure: was to demonstrate that secukinumab 150 mg s.c. is superior to placebo in the achievement of ASAS 20 response at Week 12 after superiority of 300 mg was established. 300mg and 150mg are presented side by side for clarity; and to align with protocol. 300mg data is for Primary outcome; and 150mg data is for key secondary outcome ASAS20 was defined as an improvement of ≥20% and absolute improvement of ≥10 unit (0-100 mm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (total pain score), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)
Time frame: at week 12
Percentage of Participants With Response to Treatment (150 mg/300 mg AIN457) as Assessed by the ASAS40 Criteria at Week 12
Proportion of patients with response to treatment as assessed by the Assessment of spondyloarthritis international society (ASAS) 40 criteria at week 12. ASAS40 was defined as an improvement of ≥40% and absolute improvement of ≥20 unit (0-100 mm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (total pain score), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)
Time frame: at week 12
Percentage of Participants With Response to Treatment as Assessed by BASDAI50 at Week 12
Bath ankylosing spondylitis disease activity index (BASDAI) 50 response BASDAI 50 response is defined as at least 50% improvement (decrease) in total BASDAI score.
Time frame: at week 12
Change From Baseline in Spinal Pain Visual Analog Scale (VAS) - Pain at Any Time
Change from baseline in Spinal pain visual analog scale (VAS) at week 12 VAS is a straight horizontal line of fixed length, usually 100 mm. The ends are defined as the extreme limits of the parameter to be measured (symptom,pain,health) orientated from the left (worst) to the right (best). VAS measures pain and stress for on a horizontal line of 100 mm, ranging from very low (0) to very high (100).
Time frame: at baseline, at week 12
Change From Baseline in Spinal Pain Visual Analog Scale (VAS) - Pain at Night
Change from baseline in Spinal pain visual analog scale (VAS) at week 12 VAS is a straight horizontal line of fixed length, usually 100 mm. The ends are defined as the extreme limits of the parameter to be measured (symptom,pain,health) orientated from the left (worst) to the right (best). VAS measures pain and stress for on a horizontal line of 100 mm, ranging from very low (0) to very high (100)
Time frame: at baseline, at week 12
Change From Baseline Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index Score at Week 12
The Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index score range is 0-16, where 0 is the best outcome, and 16 the worst. The assessor determines whether the site shows tenderness and therefore would count as site with enthesitis. This is done by applying pressure to the site and getting feedback from patient about whether the site is tender.
Time frame: baseline and week 12
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12
The health assessment questionnaire disability index (HAQ-DI) assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability.
Time frame: baseline and week 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue) at Week 12
The FACIT-fatigue scale is a 13-item patient-reported measure of fatigue with a 7-day recall period. Items are scored on a 0 - 4 response scale with anchors ranging from "Not at all" to "Very much so". To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52.
Time frame: baseline and week 12
Change From Baseline in Spondyloarthritis International Society (ASAS) Health Index at Week 12
Statistical analysis (using ANCOVA) of change from baseline in spondyloarthritis international society (ASAS) Health Index score by visit - treatment period 1 ASAS HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either "I agree" (score of 1) or "I do not agree" (score of 0). A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors
Time frame: baseline and week 12
Percentage of Participants With Response to Treatment as Assessed by the ACR20 Criteria at Week 12
American College of Rheumatology 20% (ACR20) Response at Week 12 is the % of responders with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1)Health Assessment Questionnaire-Disability Index (HAQ-DI), 2)C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGA-VAS)
Time frame: at week 12
503 participants completed the screening period; and the randomized set consists of 498 patients because 5 participants were misrandomized
| Milestone | AIN457 300mg | AIN457 150mg | Placebo AIN457 300 mg | Placebo AIN457 150 mg | Placebo |
|---|---|---|---|---|---|
| Started | 167 | 165 | 81 | 80 | 5 |
| Completed period 1 & went to period 2 | 162 | 153 | 81 | 80 | 0 |
| Completed | 138 | 142 | 72 | 73 | 0 |
| Not completed | 29 | 23 | 9 | 7 | 5 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 9 | 2 | 3 | 7 | 0 |
| Withdrew: Adverse event | 4 | 4 | 3 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 7 | 4 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Did not continue to period 2 | 5 | 12 | 0 | 0 | 5 |
Purpose of this measure: was to demonstrate that secukinumab 150 mg s.c. is superior to placebo in the achievement of ASAS 20 response at Week 12 after superiority of 300 mg was established ASAS20 was defined as an improvement of ≥20% and absolute improvement of ≥10 unit (0-100 mm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (total pain score), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)
| percentage of participants | AIN457 150mg | AIN457 300mg | Placebo AIN457 |
|---|---|---|---|
| Percentage of Participants With Response to Treatment (300 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12 | 66.3 (58.4 to 73.3) | 62.9 (55.2 to 70.0) | 31.2 (24.6 to 38.7) |
Purpose of this key secondary measure: was to demonstrate that secukinumab 150 mg s.c. is superior to placebo in the achievement of ASAS 20 response at Week 12 after superiority of 300 mg was established. 300mg and 150mg are presented side by side for clarity; and to align with protocol. 300mg data is for Primary outcome; and 150mg data is for key secondary outcome ASAS20 was defined as an improvement of ≥20% and absolute improvement of ≥10 unit (0-100 mm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (total pain score), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)
| percentage of participants | AIN457 150mg | AIN457 300mg | Placebo AIN457 |
|---|---|---|---|
| Percentage of Participants With Response to Treatment (150 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12 | 66.3 (58.4 to 73.3) | 62.9 (55.2 to 70.0) | 31.2 (24.6 to 38.7) |
Proportion of patients with response to treatment as assessed by the Assessment of spondyloarthritis international society (ASAS) 40 criteria at week 12. ASAS40 was defined as an improvement of ≥40% and absolute improvement of ≥20 unit (0-100 mm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (total pain score), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)
| percentage of participants | AIN457 150mg | AIN457 300mg | Placebo AIN457 |
|---|---|---|---|
| Percentage of Participants With Response to Treatment (150 mg/300 mg AIN457) as Assessed by the ASAS40 Criteria at Week 12 | 39.5 (32.1 to 47.4) | 43.6 (36.2 to 51.3) | 12.2 (7.8 to 18.4) |
Bath ankylosing spondylitis disease activity index (BASDAI) 50 response BASDAI 50 response is defined as at least 50% improvement (decrease) in total BASDAI score.
| percentage of particiapnts | AIN457 150mg | AIN457 300mg | Placebo AIN457 |
|---|---|---|---|
| Percentage of Participants With Response to Treatment as Assessed by BASDAI50 at Week 12 | 32.7 (25.8 to 40.5) | 37.4 (30.1 to 45.4) | 9.8 (5.9 to 15.6) |
Change from baseline in Spinal pain visual analog scale (VAS) at week 12 VAS is a straight horizontal line of fixed length, usually 100 mm. The ends are defined as the extreme limits of the parameter to be measured (symptom,pain,health) orientated from the left (worst) to the right (best). VAS measures pain and stress for on a horizontal line of 100 mm, ranging from very low (0) to very high (100).
| scores on a scale | AIN457 150mg | AIN457 300mg | Placebo AIN457 |
|---|---|---|---|
| Change From Baseline in Spinal Pain Visual Analog Scale (VAS) - Pain at Any Time | -28.5 ± 1.88 | -26.5 ± 1.84 | -13.6 ± 1.83 |
Change from baseline in Spinal pain visual analog scale (VAS) at week 12 VAS is a straight horizontal line of fixed length, usually 100 mm. The ends are defined as the extreme limits of the parameter to be measured (symptom,pain,health) orientated from the left (worst) to the right (best). VAS measures pain and stress for on a horizontal line of 100 mm, ranging from very low (0) to very high (100)
| scores on a scale | AIN457 150mg | AIN457 300mg | Placebo AIN457 |
|---|---|---|---|
| Change From Baseline in Spinal Pain Visual Analog Scale (VAS) - Pain at Night | -30.3 ± 1.95 | -30.2 ± 1.90 | -15.2 ± 1.89 |
The Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index score range is 0-16, where 0 is the best outcome, and 16 the worst. The assessor determines whether the site shows tenderness and therefore would count as site with enthesitis. This is done by applying pressure to the site and getting feedback from patient about whether the site is tender.
| scores on a scale | AIN457 150mg | AIN457 300mg | Placebo AIN457 |
|---|---|---|---|
| Change From Baseline Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index Score at Week 12 | -2.2 ± 0.22 | -2.4 ± 0.21 | -1.7 ± 0.21 |
The health assessment questionnaire disability index (HAQ-DI) assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability.
| scores on a scale | AIN457 150mg | AIN457 300mg | Placebo AIN457 |
|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12 | -0.330 ± 0.0360 | -0.389 ± 0.0353 | -0.155 ± 0.0351 |
The FACIT-fatigue scale is a 13-item patient-reported measure of fatigue with a 7-day recall period. Items are scored on a 0 - 4 response scale with anchors ranging from "Not at all" to "Very much so". To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52.
| scores on a scale | AIN457 150mg | AIN457 300mg | Placebo AIN457 |
|---|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue) at Week 12 | 8.0 ± 0.72 | 7.6 ± 0.71 | 4.2 ± 0.70 |
Statistical analysis (using ANCOVA) of change from baseline in spondyloarthritis international society (ASAS) Health Index score by visit - treatment period 1 ASAS HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either "I agree" (score of 1) or "I do not agree" (score of 0). A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors
| scores on a scale | AIN457 150mg | AIN457 300mg | Placebo AIN457 |
|---|---|---|---|
| Change From Baseline in Spondyloarthritis International Society (ASAS) Health Index at Week 12 | -2.9 ± 0.29 | -2.8 ± 0.28 | -1.2 ± 0.28 |
American College of Rheumatology 20% (ACR20) Response at Week 12 is the % of responders with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1)Health Assessment Questionnaire-Disability Index (HAQ-DI), 2)C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGA-VAS)
| percentage of participants | AIN457 150mg | AIN457 300mg | Placebo AIN457 |
|---|---|---|---|
| Percentage of Participants With Response to Treatment as Assessed by the ACR20 Criteria at Week 12 | 56.5 (47.5 to 65.1) | 51.6 (43.4 to 59.8) | 18.5 (13.1 to 25.5) |
Collected over Adverse events were collected from first dose of study treatment until end of study at week 12. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab 300 mg | 1/248 (0.4%) | 14/248 (5.6%) | 116/248 (46.8%) |
| Secukinumab 150 mg | 0/245 (0%) | 14/245 (5.7%) | 108/245 (44.1%) |
| Placebo | 0/166 (0%) | 4/166 (2.4%) | 47/166 (28.3%) |
| Event | Secukinumab 300 mg | Secukinumab 150 mg | Placebo |
|---|---|---|---|
| GastroenteritisInfections and infestations | 0/248 | 0/245 | 1/166 |
| PyodermaInfections and infestations | 0/248 | 0/245 | 1/166 |
| OverdoseInjury, poisoning and procedural complications | 0/248 | 0/245 | 1/166 |
| LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/248 | 0/245 | 1/166 |
| Confusional statePsychiatric disorders | 0/248 | 0/245 | 1/166 |
| Atrial septal defectCongenital, familial and genetic disorders | 0/248 | 1/245 | 0/166 |
| Abdominal painGastrointestinal disorders | 0/248 | 1/245 | 0/166 |
| Crohn's diseaseGastrointestinal disorders | 0/248 | 1/245 | 0/166 |
| DiverticulumGastrointestinal disorders | 0/248 | 1/245 | 0/166 |
| Gastritis haemorrhagicGastrointestinal disorders | 0/248 | 1/245 | 0/166 |
| Event | Secukinumab 300 mg | Secukinumab 150 mg | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 34/248 | 22/245 | 11/166 |
| DiarrhoeaGastrointestinal disorders | 16/248 | 7/245 | 4/166 |
| Upper respiratory tract infectionInfections and infestations | 12/248 | 14/245 | 5/166 |
| PharyngitisInfections and infestations | 7/248 | 13/245 | 5/166 |
| Urinary tract infectionInfections and infestations | 8/248 | 11/245 | 2/166 |
| BronchitisInfections and infestations | 11/248 | 9/245 | 1/166 |
| HypertensionVascular disorders | 4/248 | 10/245 | 2/166 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 5/248 | 9/245 | 4/166 |
| RhinitisInfections and infestations | 9/248 | 5/245 | 0/166 |
| Back painMusculoskeletal and connective tissue disorders | 9/248 | 6/245 | 6/166 |
Randomized set: All participants randomized to AIN457 300 mg/150 mg or Placebo.
| Age, Categorical(Participants) | AIN457 300mg | AIN457 150mg | Placebo AIN457 | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 159 | 156 | 157 | 472 |
| >=65 years | 8 | 9 | 9 | 26 |
| Age, Customized(Participants) | AIN457 300mg | AIN457 150mg | Placebo AIN457 | Total |
|---|---|---|---|---|
| <45 years old | 77 | 65 | 72 | 214 |
| >=45 years old | 90 | 100 | 94 | 284 |
| Sex: Female, Male(Participants) | AIN457 300mg | AIN457 150mg | Placebo AIN457 | Total |
|---|---|---|---|---|
| Female | 90 | 84 | 78 | 252 |
| Male | 77 | 81 | 88 | 246 |
| Race/Ethnicity, Customized(Participants) | AIN457 300mg | AIN457 150mg | Placebo AIN457 | Total |
|---|---|---|---|---|
| Black | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 2 | 2 |
| White | 162 | 159 | 164 | 485 |
| Unknown | 4 | 6 | 0 | 10 |
| Race/Ethnicity, Customized(Participants) | AIN457 300mg | AIN457 150mg | Placebo AIN457 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 10 | 9 | 25 |
| Not Hispanic or Latino | 139 | 140 | 146 | 425 |
| Not reported | 17 | 10 | 8 | 35 |
| Unknown | 5 | 5 | 3 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Oct 2016 to primary completion in Jun 2019, 32 months.
Results were first posted in Aug 2020, 1 year 1 month after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 32 months is above that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab